The Manila Times on MSN
DHSUD orders swift completion of stalled housing projects
THE Department of Human Settlements and Urban Development (DHSUD) on Tuesday ordered the Social Housing Finance Corp. (SHFC) to fast-track the completion of long-stalled housing projects in Caloocan ...
Outlook signals the strength of an ecosystem built on trusted regulation, strong public private collaboration, and a stable, ...
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual Meeting MIAMI, FLORIDA / ACCESS Newswire / February 3, 2026 ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
For decades, F1 had an American problem. The sport that captivated millions across Europe, Asia, and South America barely ...
Queerty on MSN
“Keep our community out of your mouth”: Nicki Minaj sparks backlash with LGBTQ+ remarks
And Billy Porter offers his own, blunt assessment of Minaj.
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the ...
The trip from Milano to Cortina, where women’s Alpine, curling and the sliding sports (bobsled, luge and skeleton) will be held, is almost five hours. Livigno, site of snowboarding and freestyle ...
Philstar Life on MSN
Get to know Asia Rose Simpson, the newly crowned Miss World Philippines 2026
The new Miss World Philippines has been crowned! Out of 24 delegates, Asia Rose Simpson of Quezon shone the brightest in this year's competition, winning the coveted crown. During the final ...
LIBERTY is a Phase 3, randomized, double-blind study to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and co-administered ...
Good morning. Welcome to the WTW Earnings Conference Call. Please refer to wtwco.com for the press release and supplemental information that were issued earlier today. Today's call is being recorded ...
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results